Lung cancer registry and monitoring: Feasibility study and application (fars lung cancer registry project)
- PMID: 37496644
- PMCID: PMC10366973
- DOI: 10.4103/jrms.jrms_760_22
Lung cancer registry and monitoring: Feasibility study and application (fars lung cancer registry project)
Abstract
Background: Lung cancer (LC) is the second most common and deadliest cancer in the world. Despite the control of the progressive course of LC in developed countries, studies indicate an increase in the incidence of the disease in developing countries. We designed a stepwise approach-based surveillance system for registering LC in our region (fars lung cancer registry "FaLCaRe" Project).
Materials and methods: A questionnaire was designed and agreed upon by the steering committee using the Delphi method. Variables in nine fields were divided into three groups based on their importance: core, expanded core, and optional. The web-based data bank software was designed. The informative site about LC and team services was designed and launched for professional and community (www.falcare.org) educational purposes.
Results: 545 variables in nine fields were designed (20 core variables). Primary data of 39 LC patients (24 men and 15 women) with a mean age of 62 years were analyzed. Twenty-six patients had a history of smoking. Moreover, 39% and 26% of patients had a history of hookah smoking and opium use, respectively. Adenocarcinoma was the most prevalent pathologic findings in cases. More than 80% of patients were diagnosed in stages 3 and 4 of cancer.
Conclusion: FaLCaRe Project with the capabilities seen in it can be used as a model for national LC registration. With continuous valid data registry about LC, it is possible to make decisions at the national level for control and management its consequences while drawing the natural history of the LC.
Keywords: Disease registration; Fars province; Iran; lung cancer; pleural malignancy; surveillance.
Copyright: © 2023 Journal of Research in Medical Sciences.
Conflict of interest statement
There are no conflicts of interest.
Figures
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. - PubMed
-
- Hazell SZ, Fu W, Hu C, Voong KR, Lee B, Peterson V, et al. Financial toxicity in lung cancer: An assessment of magnitude, perception, and impact on quality of life. Ann Oncol. 2020;31:96–102. - PubMed
-
- Huang J, Deng Y, Tin MS, Lok V, Ngai CH, Zhang L, et al. Distribution, risk factors, and temporal trends for lung cancer incidence and mortality: A global analysis. Chest. 2022;161:1101–11. - PubMed
LinkOut - more resources
Full Text Sources